Literature DB >> 26124369

Contemporary Incidence and Mortality Rates of Neuroendocrine Prostate Cancer.

Shaheen Alanee1, Aaron Moore2, Max Nutt2, Bradley Holland2, Danuta Dynda2, Ahmed El-Zawahry2, Kevin T McVary2.   

Abstract

AIM: The purpose of the study was to provide an update ever the incidence and mortality for neuroendocrine prostate cancer (NEPC) in the United States. PATIENTS AND METHODS: Using a large national database, we examined changes in age-adjusted incidence (AAIR), mortality rates (MR) and 5-year cancer-specific survival (CSS) for 378 patients diagnosed with NEPC between 1992 and 2011. Analysis was performed for all NEPC and for its two major sub-groups [small cell carcinoma (SCC) and neuroendocrine carcinoma (NEC)].
RESULTS: AAIR of NEPC continues to rise in recent years (2004-2011:+6.8%/year, p>0.05). AAIR of SCC has been increasing significantly by 6.94%/year since 2001 (from 0.470 to 0.582/1,000,000 person years, p<0.05). Overall incidence-based mortality rates for NEPC did not change significantly since 1992 and similar trends were observed for SCC and NEC.
CONCLUSION: The AAIR of SCC is increasing with no change in the MR of NEPC over the past 20 years. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  5-year survival; Prostate; androgen deprivation therapy; incidence; mortality; neuroendocrine prostate cancer; prostate cancer

Mesh:

Year:  2015        PMID: 26124369

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  20 in total

1.  [Neuroendocrine prostate cancer].

Authors:  S Tritschler; R Erdelkamp; C Stief; M Hentrich
Journal:  Pathologe       Date:  2018-07       Impact factor: 1.011

2.  Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies.

Authors:  Nikolas G Balanis; Katherine M Sheu; Favour N Esedebe; Saahil J Patel; Bryan A Smith; Jung Wook Park; Salwan Alhani; Brigitte N Gomperts; Jiaoti Huang; Owen N Witte; Thomas G Graeber
Journal:  Cancer Cell       Date:  2019-07-08       Impact factor: 31.743

Review 3.  EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers.

Authors:  Rama Soundararajan; Anurag N Paranjape; Sankar Maity; Ana Aparicio; Sendurai A Mani
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-07-05       Impact factor: 10.680

4.  [Neuroendocrine prostate cancer].

Authors:  S Tritschler; R Erdelkamp; C Stief; M Hentrich
Journal:  Urologe A       Date:  2017-11       Impact factor: 0.639

Review 5.  Advances in neuroendocrine prostate cancer research: From model construction to molecular network analyses.

Authors:  Xue Shui; Rong Xu; Caiqin Zhang; Han Meng; Jumei Zhao; Changhong Shi
Journal:  Lab Invest       Date:  2021-12-22       Impact factor: 5.662

6.  The SOX4/miR-17-92/RB1 Axis Promotes Prostate Cancer Progression.

Authors:  Hui Liu; Zhen Wu; Haibin Zhou; Wenjie Cai; Xinjun Li; Jing Hu; Lin Gao; Tingting Feng; Lin Wang; Xijia Peng; Mei Qi; Long Liu; Bo Han
Journal:  Neoplasia       Date:  2019-06-22       Impact factor: 5.715

Review 7.  Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer.

Authors:  Rodolfo Montironi; Alessia Cimadamore; Antonio Lopez-Beltran; Marina Scarpelli; Gaetano Aurilio; Matteo Santoni; Francesco Massari; Liang Cheng
Journal:  Cells       Date:  2020-04-25       Impact factor: 6.600

8.  Primary large cell prostate neuroendocrine carcinoma with central and nephrogenic diabetes insipidus.

Authors:  Cem Basatac; Sezer Sağlam; Fatma Aktepe; Haluk Akpinar
Journal:  Int Braz J Urol       Date:  2020 Sep-Oct       Impact factor: 1.541

9.  Dual Paraneoplastic Endocrine Syndromes Heralding Onset of Extrapulmonary Small Cell Carcinoma: A Case Report and Narrative Review.

Authors:  Jill B Feffer; Natalia M Branis; Jeanine B Albu
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-18       Impact factor: 5.555

10.  GRK2 enforces androgen receptor dependence in the prostate and prostate tumors.

Authors:  Adam J Adler; Payal Mittal; Adam T Hagymasi; Antoine Menoret; Chen Shen; Federica Agliano; Kyle T Wright; James J Grady; Chia-Ling Kuo; Enrique Ballesteros; Kevin P Claffey; Anthony T Vella
Journal:  Oncogene       Date:  2020-01-20       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.